Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed a 31% decrease in antidepressant use among patients who were preoperatively taking such medication, suggesting cosmetic surgery may influence antidepressant needs.

This study found a 31% decrease in antidepressant use following cosmetic surgery, suggesting that such procedures may influence medication use by improving self-esteem.

A pregnant woman's skin condition improved after giving birth, possibly due to high estrogen levels during pregnancy.

This study suggests that biotin-rich functional food may stimulate hair growth and prevent hair loss through improved cholesterol and lipid metabolism and blood flow in men.

The study suggests that CO₂ laser creates hair transplant channels with significantly less lateral thermal damage than Ho:YAG laser in the human scalp.

Obesity in the U.S. is largely influenced by diet and exercise, certain medications can improve heart procedures and hair growth, and major teaching hospitals have better patient outcomes.

Some chemicals can permanently or temporarily remove color from skin and hair, which can be distressing and is not well-regulated in cosmetics.

Taking calcium may help elderly with osteoporosis, birth control with levonorgestrel doesn't increase heart attack risk, Salmonella can cause arthritis, a national ethics committee is recommended, and sulfasalazine might help with a hair loss condition.

This abstract contains no research results but appears to be a web navigation or user interface message.

This source highlights the diverse scope of facial plastic and reconstructive surgery, noting the specialty's adaptability to changing trends and ethnic preferences for aesthetic outcomes, without reporting specific study results.

Endoscopic forehead and brow lifting safely and consistently improves aged eyebrows, but may have complications.

This brief article is a response from the authors about hair density, hair diameter, and female pattern hair loss, and it reports no new clinical findings.

This study found that patients with alopecia areata showing low treatment burden responded better to baricitinib compared to those with higher previous systemic treatment exposure.

In this report, two adult patients with Tatton-Brown-Rahman syndrome exhibited new cardiac features, such as atrial fibrillation and ventricular and atrial dilatation, highlighting the importance of cardiovascular follow-up in adults with this condition.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This study found that elevated tissue RBP4 levels correlate with disease severity in alopecia areata and decrease after effective baricitinib treatment, while the rs3758539 polymorphism is linked to disease susceptibility but not to treatment response.

This case report highlights that a patient with resistance to thyroid hormone was misdiagnosed as having Graves’ disease, leading to unnecessary radioactive iodine treatment.

In this analysis of the BRAVE-AA trials, a significant number of patients with severe alopecia areata treated with baricitinib reached complete or nearly complete scalp coverage (SALT score ≤10 or ≤5) over 52 weeks, particularly among those with less severe baseline characteristics.

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This review outlines the strategies for managing TB-IRIS in HIV patients, emphasizing early detection, prevention, and appropriate treatment to reduce morbidity and mortality.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This announcement discusses the recent FDA approval of baricitinib for treating severe alopecia areata in adults and reports no new clinical results.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.